The drug ABSORCOL contains one active pharmaceutical ingredient (API):
Ezetimibe is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol. The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Spain Italy
This drug has been assigned below unique identifiers within the countries it is being marketed: